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Inflammatory activation of microglia is a hallmark of several disorders of the CNS. In addition to protecting the
brain against inflammatory insults, microglia are neuroprotective and play a significant role in maintaining
neuronal connectivity; therefore, the prolongation and inflammatory status may limit the beneficial functions
of these immune cells. The findings that estrogen receptors are present in monocyte-derived cells and that
estrogens prevent and control the inflammatory response raise the question of the role that this sex hormone
plays in the manifestation and progression of pathologies that have a clear sex difference in prevalence, such
as multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. The present review aims to provide a critical
review of the current literature on the actions of estrogen in microglia and on the involvement of estrogen
receptors in the manifestation of selected neurological disorders. This current understanding highlights a
research area that should be expanded to identify appropriate replacement therapies to slow the progression
of such diseases.
I. Introduction
THE NERVOUS SYSTEM is not readily accessible toperipheral immune cells, but evolution has favored
the selection of microglia as the resident immune cells in
the central nervous system (CNS) for the first line of pro-
tection against noxious stimuli, such as stress and patho-
genic insults. To adapt to the needs of their environment,
microglia are extremely plastic cells able to show an array
of diversified phenotypes. Indeed, in response to a poten-
tial danger,microglia perform the following: i.) synthesize
and release inflammatory molecules (eg, TNF, reactive
oxidative species, inflammatory cytokines and chemo-
kines); ii.) alert the brain and other immune cells, iii.) clear
all debris in the parenchyma and vi.) provide nutrients to
repair the damage induced in the cells surrounding the
inflammatory battlefield; in addition, mounting evidence
indicates that v.) microglia play amajor supporting role in
neurogenesis and neuronal activity.
In the case of major injury, microglia attract peripheral
immune cells to form an integrative network (with astro-
glia, neutrophils, lymphocytes, plasma cells, and macro-
phages) that provides the brain with a strong defensive
system. This functional complex is finely regulated by a
well-timed synthesis of inflammatory and anti-inflamma-
tory molecules for the transient inception of the inflam-
matory response in the presence of insults and to return to
a surveying stage as the immune emergency is resolved.
Failure of such homeostatic mechanisms may have severe
pathological consequences, as an excessive, prolonged or
asynchronous immune activation plays a very active role
in the onset and progression of pathologies ranging from
chronic pain and epilepsy to neurodegeneration and psy-
chiatric disorders (1–4).
An emerging theme in the study of microglia function
is the sex-related differences highlighted by a growing
number of studies in male and female vertebrates. The
precise roles played by genetic, hormonal or environmen-
tal cues in determining this sexual dimorphism remain to
be clarified. Certainly, estrogens play a major role in con-
trolling microglia activity. In this review, we will discuss
recent advances in theunderstandingofmicroglial biology
with a particular focus on the influence of estrogens on
their function and on the physio-pathological relevance of
this regulation. Furthermore, we will highlight the areas
that need tobe explored to verify the potential for estrogen
receptor ligands in the attenuation of neuroinflammation
in specific neuronal disorders.
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Microglia: the immune cells of the CNS
a. Microglia and brain development
i. Microglia and structural organization of the
developing brain
The existence of microglia was first described by Nissl
in 1880. In the first decades of the twentieth century, the
seminal work of Santiago Ramon y Cajal and his student
Pio Del Rio Hortega formed the basis for determining the
morphological and functional differences between micro-
glia and other neural cells (5, 6).Microglia, unique among
the major cell types in the CNS, are not derived from the
ectoderm. In fact, during early fetal development, a major
wave of myeloid precursors migrate from the embryonic
yolk sac to the brain to become the resident microglia.
Accordingly, genetic and cell lineage studies show that
microglia originate from Pu.1 positive cells in both the
mouse (7) and zebrafish (8), and fate-mapping experi-
ments show colonization of the brain by CSF1R erytro-
myeloid progenitors at embryonic day 8.5 (9, 10). The
number of microglia precursors that migrate to the brain
around embryonic day 8.0 (10) is finite and relatively
small (8) but sufficient to proliferate, populate the entire
brain and self-maintain for an entire life span. The factors
required for brain colonization have yet to be completely
identified. In mice, colony stimulating factor 1 (CSF1) is
involved because mouse embryonic microglia express
CSF1 receptor and Csf1 gene deletion results in a signif-
icant loss of microglia in adults (10, 11). It is conceivable
thatmacrophagesmigrate in response to an inflammatory
stimulus, as indicated by genetic studies conducted in ze-
brafish (12) and by the fact that in the developing brain,
microglia are generally large round amoeboid cells that
produce elevated levels of cytokines and chemokines.
Microglia phagocytic activity contributes to the struc-
tural organization of the developing brain by eliminating
redundant neurons and synaptic connections (13) (Figure
1.). Microglia-dependent synaptic pruning is well-docu-
mented in the developing hippocampus and thalamus,
where in the presence of the complement system, these
Figure 1.
Microglia are a dynamic mediator of synaptic development and homeostasis. Microglia in its surveying state senses the state of
activity of neurons, is attracted to the dendritic spines through proteins of the complement and fractalkine and participates in neuronal plasticity
potentially through the release of proteases able to modulate the structure and functions of the synapses. Microglia possibly respond to the
release of ATP which may induce the shedding of lipid-rich vescicles that were reportd to increase the frequency and amplitude of the excitatory
postsynaptic potential (EPSC).
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cells engulf PSD-95-containing postsynaptic dendritic
spines driven by the fractalkine system (14). The phago-
cytic actions ofmicroglia play a central role in the removal
of apoptotic neurons (15), as well as inducing death in
selected populations of viable neurons through a process
called phagoptosis (16). The chemokine fractalkine
(CX3CL1) released by the dying cells attracts phagocytic
microglia, and the neurons to be engulfed are recognized
by the phosphatidylserine (PS) exposed on the external
surface. Inaddition, time-lapsemicroscopy in thebrainsof
rodents and monkeys and in organotypic cortical slices
showed that microglia phagocytose neural precursors in
the cortex (17) and cerebellum (18). The criteria for the
selection of the neurons to be eliminated during develop-
ment require further investigation. However, the fact that
microglia sense synaptic activitymay suggest that the neu-
rons eliminatedare thosenotactively establishing synaptic
contacts with their peers (19, 20). Finally, microglia pro-
mote the survival of neurons and the growthof their axons
(21) through the secretion of neurotrophic factors, such as
IGF-1, IL-1 and IFN (22). Such a function ismaintained
in the adult brain, as discussed later.
ii. Microglia colonization of the brain is sex dependent
The colonization of the developing mouse brain by mi-
croglia appears to occur differently in the two sexes be-
cause males were shown to have overall more microglia
early in postnatal development (P3-P4). This is in contrast
with the fact that females have more microglia in selected
brain areas later in development and in adulthood (23).
The developing male hippocampus and cortex have a
nearly 200-fold greater expression of the chemokine li-
gand CCL20 and 50-fold higher expression of the chemo-
kine ligand CCL4 than those of females. Conceivably,
these two chemokines play critical roles in driving the di-
morphic perinatal colonization of brain regions relevant
for cognition and memory, as well as a role in the highly
sexual dimorphic POA region (23, 24). The cause of the
elevated levels of chemokines in the developingmale brain
remains unknown, but the temporal correlation between
microglial brain colonization and the surge of testicular
activity (at day E17) suggests the involvement of sex hor-
mones (25) (Figure 2.). Additional investigations during
brain maturation are necessary to learn whether sex hor-
mone receptors have a sexual dimorphic expression. Mi-
croglia from P3 mice express ER (26), and the mRNA
content for this receptor subtype further increases in adult
mice, suggesting that microglia sensitivity to estrogens in-
creases with age (26). So far, no sexual differences were
observed in ERmRNA content at any age (26, 27). ER
mRNA was detected in microglia primary cultures from
P0 newborns (28), while the levels of this receptor are
undetectable in microglia sorted ex vivo from mice at P3
and from adults (26, 27). The data provided so far on the
expression of the progesterone receptor (PR) and andro-
gen receptor (AR) indicate that these receptors are not
expressed in microglia in adult mice (27).
A sexually dimorphic behavior of microglia during de-
velopment may be important because preor peri-natal in-
fections may induce permanent neurological conse-
quences. Indeed, excessivemicroglia activation during the
developmental programming has been implicated in al-
tered sexual behavior (29); dopamine-mediated functions
and cognitive abilities (25, 30); a predisposition to mental
disorders, such as schizophrenia and autism (31); and in
neurological alterations that have adifferent occurrence in
males and females (31). This argues for the necessity of
further investigation on the role played by the endocrine-
microglia communication in the structural organizationof
the brain.
b. Microglia in the adult, healthy brain
In the adult nervous system, microglia are distributed
throughout the brain with slight changes in concentra-
tions and activity in each region (32, 33). In the human
brain, microglia account for up to 16% of all non-neuro-
nal CNS cells and reside mainly in the white matter. In the
rodent brain, microglia are found more often in the gray
matter, and their content is lower (5%–12% of all glial
cells) (32, 34).Observations in transgenicmicewith aGFP
reporter located under the control of the promoter for the
fractalkine receptor gene (Cx3cr1) (35) demonstrated that
microglia cells never rest and are constantly patrolling the
brain parenchyma. Even in the absence of inflammatory
stimuli, the processes extending from the cell somata are
in continuousmotion and growth, retracting andprotrud-
ing in filopodia-like membranes with a bulbous ending
(34). In this “surveillance” state aimed at detecting acute
or chronic injuries, microglia movements are regulated
internally by K/Cl- cotransporters that mediate process
swelling (36) and by depolymerization and repolymeriza-
tion of actin filaments. These changes are induced by en-
vironmental cues, such as glutamate acting through mi-
croglia 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl
propanoic acid (AMPA) receptors (37), or purinergicmol-
ecules (38) and components of the complement system (5,
39). Through this activity, microglia monitor three-di-
mensionally the microenvironment (34) and fulfill their
large number of housekeeping functions (eg, removal of
cellular waste products and cell debris, remodeling of ex-
tracellular matrix, reshaping of synapses and neuronal
connectivity) (40). In addition, microglia secrete growth
factors (transforming growth factor (TGF), fibroblast
growth factor (FGF), nerve growth factor (NGF) (41)) and
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lipoproteins, thus participating in stem cell proliferation
(42), neuronal dynamics and maintenance of neuronal
membranes.
When in the surveying state, which is characterized by
a highly ramified phenotype, healthy microglia are not
believed to secrete inflammatory molecules. Once chal-
lenged by physical or chemical insults (infection, trauma,
oxygen deprivation), microglia are “activated” and ac-
quire an amoeboid, macrophage-like, morphology, be-
coming phagocytic and able to secrete a large variety of
inflammatory molecules. Activated microglia move more
rapidly and may cover relatively large distances in the
brain parenchyma. Several other morphological features
have been described formicroglia. For instance, in chronic
disorders, microglia might acquire a rod-like shape or be-
come multinucleated and increase their dimensions in the
presence of indigestible material. Finally, microglia might
present processes that are short and stocky. This latter
morphology is often observed in aging brains and is con-
sidered dystrophic (43).
All these phenotypes reflect a differential functional
statuswith the expression of biochemicalmarkers that are
very useful for amore objective definition of themicroglia
functional status (Table 1). In their surveying stage, these
cells express low levels of myeloid-monocytic markers,
such as Fc receptor-cluster of differentiation (CD) 32 and
CD64, integrins (CD11b and CD11c), major histocom-
patibility complex (MHC) classes I and II and CD45 (44).
In the presence of specific stimuli, such as tissue damage,
the so-called ‘damage-associated molecular pattern’
(DAMPs) released by the injured cells induce microglia to
transition to a proinflammatory state. In this “classical
activation”, or M1 state, microglia retract their ramifica-
tions, potentiate phagocytic activity, and increase the ex-
Figure 2.
Brain development: the sexually dimorphic activity of microglia. Primitive macrophages exit the yolk sac blood islands at the onset
of circulation and colonize the neuroepithelium from E8.5 to give rise to microglia. The blood brain barrier starts to form from E13.5 and may
isolate the developing brain from the contribution of fetal liver hematopoiesis. Embryonic microglia expand and colonize the whole CNS until
adulthood. The high concentration of chemokines in the male brain facilitates microglia proliferation.
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pression of cell surface proteins relevant for the innate
immune response, such as Toll-like receptors (TLR), in-
flammasome, phagocytic and scavenger receptors, and re-
ceptors for advanced glycation of end products (RAGE)
(45–54). TheM1 state is also associated with the produc-
tion of cytokines and chemokines, in particular CCL2
(also named monocyte chemotactic protein-1, MCP-1),
which is responsible for the recruitment and migration of
additionalmicroglia to the insult site (55). In theM1 state,
microglia also show increased expression of phagocytic
oxidase (PHOX) (56) and inducible nitric oxide synthase
(iNOS) (57), as well as the increased generation of nitric
oxide, the main cytotoxic mediator in acute and chronic
inflammatory responses (58) (Table 1).
This host defense mechanism, which is very effective in
taming inflammation, may cause local collateral damage.
Thus, upon removal of the inflammatory stimuli, an elab-
orate and organized response is required to replace lost
and damaged cells and to restructure the damaged extra-
cellular matrix (ECM), with the final aim to restore tissue
homeostasis. At this point, microglia change their pheno-
type and promote the blockade of the immune response
and the commencement of specific programs aimed at re-
pairing the damaged tissue (59). This activity is carried out
in concertwith glia and neurons and includes the synthesis
and secretion of specific anti-inflammatory cytokines,
which are responsible for the transition of microglia to
other functional phenotypes (60) (Table 1). In particular,
IL-4 and IL-13 induce the “alternative activation” (or
M2a phenotype) responsible for the resolution of the in-
flammatory phase by indirectly repressing the production
of proinflammatory cytokines and the expression of iNOS
(61, 62). Ligationof immunoglobulin Fc gamma receptors
(FcRs) (CD16, CD32 or CD64) by immune complexes
on LPS or IL-1 primed microglia results in the “type II
alternative activation” (M2b phenotype), leading to
downregulated expression of IL-12, increased IL-10 se-
cretion and increased MHC-II expression (Table 1). The
dampening of the inflammatory response is also associ-
atedwith the “acquired deactivation” phenotype (orM2c
phenotype), characterized by the production of IL-10 and
TGF, anda strong repressionofMHC-II (Table1).These
cytokines account for trophic effects and tissue remodel-
ing functions, including remodeling of the ECM (63), an-
giogenesis (64), and, in neurotrophic niches, neurogenesis
(65). The acquired deactivation stage can also be induced
by the presence of apoptotic cells as microglia recognize
the PS exposed on the surface of apoptotic neurons (66).
Soluble bridging molecules, such as the adapter protein
growth arrest-specific 6 (Gas6) (67), bind to PS through
their GLA domain (N-terminal 11 -carboxyglutamic
acid residue), thus serving as eat-me signals that are rec-
ognizedby receptor tyrosine kinases (68) on themicroglial
membrane (Tyro3, Axl, and Mer - TAM). In chronic in-
flammatory diseases associated with aging, this trophic
function appears to be impaired (69), possibly in relation
to a decline in Gas6 expression. These different stages of
activation do not have well-defined boundaries, but they
represent a continuum among each other, and similar to
peripheral macrophages, they are classified on the basis of
the genes the preferentially express (Table 1).
i. Microglia - astrocyte interactions
The anatomical changes induced by injury and disease
in astrocytes were describedmore than 100 years ago.We
nowknow that reactive astrocytes protect neural cells and
Table 1. Molecular characterization of microglia phenotypes
Inflammatory (M1) Alternative Activation (M2a)
Type II alternative
activation (M2b) Acquired Deactivation (M2c)
Function Killing of intracellular pathogens Extinction of inflammatory response Immunoregulation
Pathogen phagocytosis Killing of encapsulated parasites Engulfment of apoptotic/dead cells
Extracellular matrix degradation Extracellular matrix deposition
Tissue remodeling
Markers 1 TLRs 1 Polyamines 1IL-10 1 TGF
1 CR1, CR3, CR4 2 IL-12 2 IL-12 1 IL-10
1 CD36, CD91 2 iNOS 1CD16 2 IL-12
1 RAGE 1 IL-1ra 1CD32 1 Versican
1 NF-B 1 CD163 1CD64 1 PTX3
1 TNF- 1 CD206 1 MHC-II 1 MARCO,
1 IL-1, IL-6 1 MHC-II 2 MHC-II
1 IL-12, IL-23 1 Arg-I, Ym-1, Fizz-1 1 TIMP1
1 CCL2 1 TREM-2 1 CD163
1 iNOS, PHOX 1CD 33
1 MHC-II
1 MMPs
1 TREM2
1 IL-6
1 CD14
1 CD40
1 CD74
1 CD68
Stimulus IL-1; TNF; (IL-6) IL-4; IL-13 LPS; IL-1 IL-10; TGF
References (309–312) (59 313 314) (315) (59 313)
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tissues by several means that include the following: i.) the
modulation of synaptic activity through the uptake of po-
tentially toxic molecules, such as glutamate (70), or the
blockage of transporters for inhibitory peptides, such as
-aminobutyric acid (GABA) (71); ii.) the release of glu-
tathione and adenosine to control oxidative damage (72,
73) and iii.) the degradation of protein aggregates in the
brain parenchyma (74). Microglia activation and astro-
gliosis are commonly observed in the case of brain injury,
infection and neurodegenerative diseases; however, we
lack the necessary insight into the functions of the bidi-
rectional cross-talk occurring between these two cell
types. The seminal work by Gan and colleagues based on
in vivo transcranial time-lapse, two-photon imaging dem-
onstrated that after a small laser insult, microglia near the
site of injury responded within a few minutes, and micro-
glial processes converged to the site of injury driven by the
ATP released from astrocytes (75), recognized by the
P2Y12G-coupled receptors expressedby the surveyingmi-
croglia (76). Prior in vitro studies led to thehypothesis that
astroglia may attenuate microglia reactivity or facilitate
the resolution of the inflammatory response. This would
occur through the synthesis and release of GABA, which
decreases microglial production of inflammatory cyto-
kines (77) and microglia expression of antioxidant mole-
cules (eg, hemeoxygenase-1) regulated by the erythroid
2-related factor, Nrf2 (78). In turn, initial studies point to
a microglia-mediated modulation of astrocytes through
the release of purines (79) or other inflammatory mole-
cules, such as prostaglandin D2 (PgD2), that are known to
induce astrogliosis (80). The development of methodolo-
gies for the isolation and culture of pure populations of
microglia or macroglia demonstrated that astrocytes are
insensitive to inflammatory stimuli, and their ability to
produce regulators of the proteolytic balance (tissue in-
hibitors ofmetalloproteases orTIMPs) in response tomol-
ecules, such as LPS is mediated by microglia (81). This
function was shown to be necessary for the survival of
neurons after ischemic insult and in demyelinating dis-
eases (82, 83). The finding of a reciprocal regulation be-
tween microglia and astrocytes in the control of neuroin-
flammation demands additional studies to better
understand the extent to which impairments of this two-
way communication is associated with the onset of CNS
disorders.
ii. Microglia - interactions with other immune cells
Another important function of microglia is the presen-
tation of foreign antigens to T lymphocytes. In the healthy
brain, antigen-presenting cells (APC) are represented by
macrophages and dendritic cells in the meninges, choroid
plexus and perivascular spaces. Activated microglia up-
regulate the expression of the molecules that are needed
for an optimal APC function (84). It is still controversial
whethermonocytes contribute to theadultmicroglial pop-
ulation.The current belief is that althoughmonocytesmay
penetrate the adult brain and differentiate into microglia,
these cell are short-lived and an unlikely source for main-
taining the microglia population in steady-state condi-
tions. However, during certain neuroinflammatory pa-
thologies (eg, multiple sclerosis (MS) or Alzheimer’s
disease), the recruitment of circulating bone marrow pro-
genitors can supplement, to some extent, the microglial
population (85, 86).
i. Microglia - neuron interactions
The intimate relationship between neurons and micro-
glia in the adult brain is believed to be the recapitulation
ofwhatwasalreadydescribed formicroglial development.
In the mature nervous system, the major form of commu-
nication between neurons and microglia is the fractalkine
receptor, CX3CR1, but other proteins may be involved
(eg, CD200 and receptors for neurotransmitters and neu-
ropeptides). Microglia are the only brain cells that can
express high levels of the CX3CR1, a G-protein coupled
activated by the CX3CL1 ligand, a transmembrane gly-
coprotein that may be released by neurons after proteo-
lytic cleavage as a consequence of cytotoxic or other stim-
uli. The activation of the fractalkine receptor serves two
main purposes: i.) modulation of synaptic pruning (14)
and ii.) constraint of microglia activation.
Recent molecular imaging studies with two-photon la-
ser microscopy showed that surveying microglia stop and
regularly interact with all synaptic elements (the presyn-
aptic terminal, perisynaptic process and synaptic cleft, but
not the dendritic shaft); these contacts last for a highly
variable period of time (20). It is important to note that the
frequency of these contacts is relative to neuronal activity.
For instance, in the case of ischemia induced by transient
occlusion of the middle cerebral artery, the durations of
microglia-neuron contacts are significantly prolonged
(from minutes to an hour). During that period, several
presynaptic terminals disappear, clearly suggesting that
microglia may control spine densities in relation to neu-
ronal activity (14, 20). The study ofmice deficient in com-
plement C1q or C3 showed defects in the elimination of
CNS synapses (87), supporting the hypothesis of an in-
volvement of the complement in microglia regulation of
synaptic functions (Figure 1). In addition to the CX3CR1,
microglia are equipped with a plethora of receptors for
neurotransmitters and neuropeptides, such asGABA, glu-
tamate and Substance P (88), enabling microglia to sense
neuronal activity, synthesize and secrete inflammatory
mediators, neurotrophic factors or modulators of its own
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phagocytic activity (89). When damaged, neurons may
attract microglia by releasing neurotransmitters, such as
glutamate (90) or other signals such as growth factors (eg,
FGF-2) (91).Oncenearneurons,microglia receptors sense
neuronal activity and leadmicroglia to participate in plas-
tic changes at the synapse through several mechanisms
(41, 89). In the case of neuronal death, microglia are rap-
idly activated to clear the apoptotic cell debris, which
could be harmful for the bystander neurons (51, 92).
Neurons, in turn, have the means to control the tran-
sition of microglia into the inflammatory phenotype and
may increase the threshold of microglial sensitivity and
reactions to neurotoxic stimuli. For instance, inCX3CR1-
deficient mice (93, 94), the state of microglia activation in
response to stimuli, such as LPS or 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), was much higher
than that in wt animals. Depending on the circumstances,
neurons may facilitate the resolution of the inflammatory
status and induce microglia to synthesize trophic factors
relevant for neuronal health. Thus, the neuron-microglia
reciprocal modulation must be kept under a tight balance
as microglia may be relevant for a homeostatic neuronal
signaling, by its excessive activity may damage neurons.
This was noted by several in vitro studies that emphasized
the damage-exacerbating effects of microglia-derivedNO
after prolonged stimulation with LPS (95–97), glucose
stimulation or ischemia (98, 99). High NO levels inhibit
neuronal respiration, causing the release of glutamate (96,
97), and NMDA receptor-mediated neurotoxicity is po-
tentiated by the presence of activated microglia. This
mechanism may recapitulate physiological events neces-
sary for brain development, which in the adult healthy
brain are kept under control because neurons may limit
microglia negative influences by releasing substances able
to induce apoptosis of activated microglia (100, 101).
All together, these observations support the vision that
microglia are a very significant complement to astrocytes
in the regulationof neuronal synaptogenesis, transmission
and survival (40). However, at the same time, they under-
line the necessity of a continuous control of microglia
functions for the activity of neurons.
c. Energy metabolism and neuroinflammation
Diet-induced obesity is associated with neuroinflam-
mation (102), heightened cytokine levels in several brain
regions (103, 104), hippocampal synapticmalfunctioning
(105), altered neurogenesis (106) and cognitive impair-
ment (103, 105). In rodents, within the first week of con-
suming a high-fat diet, markers of neuronal injury were
observed in the arcuate nucleus of the hypothalamus and
in the adjacentmedian eminence thatwere associatedwith
reactive gliosis involving both microglia and astroglia
(107). This effect was reversible and was generated by
saturated, but not unsaturated fatty acids (107), indicat-
ing the existence of a selective mechanism. However, a
continued exposure to a high-fat diet (HFD) led to a per-
manent activation of microglia (but not astroglia) in the
mediobasal hypothalamus that was observed also in hu-
mans by means of magnetic resonance imaging (MRI)
(108). Exercise reduces neuroinflammation, and this
could be due to an improved glucose tolerance (109).
However, considering that the effects of HFD were cir-
cumscribed to the brain regions responsible for the control
of energy homeostasis and that the peptides MSH and
NPY induce cytokine and nitric oxide production by mi-
croglia, it is tempting to speculate that the activity of an-
orexigenic and orexigenic neurons in response to an un-
balanced diet may be the trigger for microglia activation
(78, 95, 110, 111). A better understanding of this phe-
nomenon is relevant for humanhealthbecauseobesity and
metabolic syndrome are important risk factors for the de-
velopment of Alzheimer’s disease (112–115), and obese
patients show deficits in learning, memory and executive
functioning (116).
Most interestingly, in animal studies, young females
were shown to be refractory to diet-induced neuroinflam-
mation; ER KO female mice fed a chronic HFD diet be-
haved similarly to wt males. This suggests that estrogens
and their receptors may regulate the neuroinflammatory
response, and in females, circulating estrogens may play a
protective, anti-inflammatory role. What remains to be
established are the mechanisms through which estrogens
may modulate microglial inflammatory responses: estro-
gens may directly regulate the inflammatory genes, but
may also regulate the production of compounds (such as
NPY) triggering inflammation in the hypothalamic pep-
tidergic neurons, which are known to express ER and to
be susceptible to the actions of estrogen (117, 118).
d. Microglia and aging
Aging is the major risk factor for the development of
neurodegenerative diseases (ND), and several large-scale
genetic studies have implicated microglial molecules in
sporadic forms of ND, thus giving strength to the hypoth-
eses of a prominent role of neuroinflammation in the onset
and progression of ND. The general consensus is that, in
the adult brain, microglia protect and defend other neural
cells from pathological insults, but we know very little
aboutmicroglia efficiency in a senescent brain. Therefore,
the compellingquestion iswhether senescentmicroglia are
able to maintain their proliferative and brain patrolling
capacity together with their responsiveness to pathologi-
cal insults? As previously mentioned, the microglia mi-
grated from the embryonic yolk sac proliferate and self-
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renew throughout the entire life span. This suggests that
microglia live for long periods and may somewhat un-
dergo senescence by losing their efficiency and depriving
thebrainof its natural defense (119, 120).The finding that
with aging there is an increased density of microglia in
several brain regions (121, 122), suggests that the capacity
to proliferate is maintained in time. This poses the ques-
tion as to whether such a life-long process leads to telo-
mere shortening and the loss or gain of functions associ-
ated with the replicative senescence. In fact, we still know
very little about the existence of the stem-like microglia
progenitors proposed by Elmore et al (11), even if the
heterogeneous distribution of microglia in the aging brain
might support theviewof subpopulationsof cells through-
out the parenchyma (122, 123). The few studies address-
ing the analysis of microglia morphology in aging brains
show that aged human and rodent microglia are less ram-
ified withmore tortuous processes carrying some bulbous
swellings (43, 124). The motility of microglial processes
appears to be diminished by age, as was indicated by in
vivo imaging studies (125, 126) and by transcriptomic
analysis, which found that young microglia express more
motility genes than old microglia (127). Immuno-pheno-
typing and biochemical studies established that aging is
associatedwith a general upregulation ofmarkers that are
typical of the proinflammatory state, and microglia are
more readily responsive to toxic insults (128–131).On the
other hand, at least in rodents, markers of the microglia
anti-inflammatory state were shown to be increased with
age (124, 128). The studies conducted so far may at times
appear contradictory because microglia might respond
very differently in relation to the pathological context in
which theyare studied.Therefore, conclusive results could
be drawn only from studies carried out in healthy aged
brains (Figure 3.). However, the ability to engulf and de-
grade the extracellular material resulting from the phago-
cytosis process remains underinvestigated in senescentmi-
croglia. Histological studies in the brains of aged, healthy,
humans or animals have shown accumulation of protein
aggregates in the parenchyma. However, it is unclear
whether this is the consequence of an age-dependent ab-
normal production of aberrant proteins or their lack of
clearance due to a decreased microglia phagocytosis. It is
likely that both mechanisms are occurring, as it is con-
ceivable that aging correlates with a decreased ability of
microglia to proteolytically digest the engulfed protein ag-
gregates and debris from the surrounding space with a
consequent impairment of the phagocytotic process (132).
In addition to brain local events triggering microglia ac-
tivity, the generalized, systemic, inflammation that ac-
companies aging in mammals may provide a significant
contribution to inducing a proinflammatory, dysfunc-
tional state of these cells that is also facilitated by the
increased permeability of the brain–blood barrier de-
scribed in aged organisms (84, 133–135).
Mechanisms of estrogen actions in microglia
a. Estrogens may modulate target cell activity by
interacting with several receptors
i. Intracellular receptors ER and ER - structure
In mammals, two isoforms of the ER have been de-
scribed. They are referred to as and
, with each encoded by a separate
gene (ESR1 andESR2, respectively).
The structure of the two receptors is
very similar; however, the functions
of the twomay differ considerably in
different cell systems (136). (Figure
4.)
ii. Intracellular receptors ER and
ER - functions
Inhibitory proteins.
In the absence of the cognate li-
gand, ERs are in a complexwith pro-
teins that prevent the receptor bind-
ing to theDNA (heat shock proteins,
Hsp90, Hsp70 and other chaper-
ons). The complex is mainly, but not
exclusively, localized in the cell nu-
cleus (137, 138). Upon binding the
Figure 3.
Morphological and functional elements point to alterations of microglia
activity with age.
8 Estrogens, Neuroinflammation and Neurodegeneration Endocrine Reviews
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 05 June 2016. at 09:23 For personal use only. No other uses without permission. . All rights reserved.
cognate ligands, these receptors undergo conformational
changes that lead to the release of inhibitory proteins, thus
unmasking the DBD.
Post-translational modifications.
ER activity, prior to and after DNA binding, is regu-
lated by a constellation of post-translational modifica-
tions (PTM). These modifications include the following:
phosphorylation, acetylation, methylation, sumoylation,
and palmitoylation (139). This large variety of PTM reg-
ulates the half-life of the receptor proteins, as well as their
cellular localization (140), and their ability to interact
with DNA and other signaling proteins (141). Thus, PTM
are necessary to tune the receptor functions in relation to
cues present in the host cell and in the whole organism.
Moreover, initial studies have demonstrated that the state
of PTMof ERs is highly plastic and significantly regulated
by the hormonal milieu. To provide an example of the
multiple consequences of PTM, ER phosphorylation
(whichmayoccur at 10different serine/threonine/tyrosine
residues) is necessary for the receptor dimerization and the
recruitment of specific transcription factors, such as p160
coregulators with chromatin remodeling enzymes (142).
ER activation in the absence of natural or synthetic ligands.
Ligands are generally required to activate sex hormone
receptor transcriptional activities.However, it is nowwell
established that these receptors may also be activated in
the absence of a ligand (unliganded activation). This phe-
nomenon, initially proposed by O’Malley’s group for the
progesterone receptor (143, 144), was then supported by
a large series of observations in other nuclear receptors
includingERs. It is nowwell accepted that unligandedERs
can be activated by growth factors (such as epidermal and
Figure 4.
Structure and PTM sites of the nuclear estrogen receptors.
Like all steroid receptors, the ERs belong to a family of hormone modulated-transcription factors characterized by the presence of 6 functional
domains: A-B. the N-terminal domain that contains the activation function 1 (AF-1) enabling the interaction with coregulators also in the absence
of the ligand; C. the highly conserved DNA binding domain (DBD), responsible for the recognition of specific DNA sequences (named estrogen
responsive elements, ERE) through the two Zn fingers; D. the hinge region, a flexible domain that connects DBD with the ligand binding domain
(LBD) able to influence intracellular trafficking and subcellular distribution; E. the LBD responsible for ligand recognition that contains the ligand-
dependent activation function 2 (AF-2); the LBD, contributes to the dimerization interface of the receptor in concert with the DBD; F. the C-
terminal domain that participates in the binding to ligands. Both ERs unrdego a large number of regulatory post-translational modifications
exemplified in the figure (human ER and murine ER).
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the insulin-like growth factors) (145–147) through the in-
volvement of selected kinases (MAPK, PKA and p21 ras/
ERK) (148–151).A seriesofbiochemical andgenetic stud-
ies suggested the existence of cell-specific phosphorylation
sites required for unliganded receptor activation (eg, Ser
118 in COS-1 cells and Tyr 537 in neuroblastoma cells)
(152).
Protein-protein interactions.
ER PTM involves their interaction with other proteins,
such as calmodulin, cyclin D1, BRCA-1 and transcription
factors (eg, c-fos, c-jun) that may modify receptor func-
tions (153, 154). The interaction with coregulators is es-
sential for the modulation of target gene transcription be-
cause it enables the recruitment of general transcription
factors to the TATA box and histone modification to fa-
cilitate RNA pol II transcription of the target genes (155,
156).
ER intracellular signaling:Once activated by ligands or
by PTM, ERs regulate the activity of their target cells by
several mechanisms that include the following: a.)
dimerization that enables recognition and binding of
EREs in the promoter of target genes and interaction with
coactivator and corepressors to promote/repress tran-
scription; b.) binding to other nuclear transcription fac-
tors (eg, AP-1, NF-B) interfering with their transcrip-
tional capacity; c.) binding to cytoplasmic molecules
involved in signal transduction (eg, Src, PI3K, STATs) and
alterations of their signaling (157).
iii. Intracellular ER and ER may translocate to the cell
membrane to regulate specific cell functions
Monomers of the classical intracellular ER and ER
may be induced to migrate to the cell membrane and as-
sociate with caveolae (158) by serine palmitoylation
(C451/447 formouse/humanER) (140). In the cellmem-
brane, estrogen binding induces dimerization of the ER
and rapid signaling through G and G proteins (159).
The association with G proteins was shown to occur in a
cell- and context-specificmode to provide the appropriate
cell response to various stimuli. A rapid process of depal-
mitoylation regulates the length and extent of this signal-
ing (160). The number of intracellular receptors that are
palmitoylated and transported to the membrane is a frac-
tion of the total (approximately 5%–6% of all ERs), yet
it is sufficient to have a significant impact on glucose and
lipid metabolism in different cell types (161, 162). The
recent generation of a mouse with a mutation at aa 451
(C451A) finally demonstrated that this receptor localiza-
tion is essential at least for ovarian functions (163). Nev-
ertheless, little is known so far about its functions in the
CNS.
iv. The pharmacology of intracellular ER and ER
In the last 50 years, a number of synthetic ER ligands
were generated and developed for clinical use. These li-
gands include the following: clomiphene, tamoxifen,
toremifene, raloxifene, bazedoxifene andospemifene.The
commoncharacteristic of these ERmodulators is that they
were selected to circumvent the use of natural estrogens
due to their potential effects on endometrial and breast
cancers. These compoundswere named selective ERmod-
ulators (SERMs) because they bind the ER, but their ag-
onist-antagonist effect is tissue dependent. Thus, most of
the SERMs have antagonistic actions on ER in reproduc-
tive tissues. The first and second generation SERMs, ta-
moxifen and raloxifene, are used to treat ER-positive
breast cancer and postmenopausal osteoporosis, respec-
tively. The third-generation SERM, bazedoxifene (BZA),
effectively prevents osteoporosis while blocking estro-
genic stimulation in breast and uterine tissues. Unfortu-
nately, the specific estrogenic vs. antiestrogenic effects of
SERMsonneuronal, glial ormicroglial cells have not been
fully determined. The ability of these ligands to exert a
tissue-specific action is attributed to the fact that by bind-
ing the ligand pocket of the ER, they induce conforma-
tional changes that are quite different than those of the
E2-ERcomplex, this possibly limits their ability to interact
like natural estrogens with the coregulators (164). Selec-
tive ER down-regulators (SERDs, or pure antiestrogens),
an alternative to SERMs, are characterized by a different
activity because they cause downregulation and degrada-
tion of ERs. The prototype of a SERD is fulvestrant (ICI
182 780).More recently, the identificationofmicroRNAs
that can directly target ERs raised major interest particu-
larly in the cancer field. The mechanisms involved in the
miRNA-dependent modulation of ERs varies among the
miRNAs isolated; most regulate the content of ER indi-
rectly, others, such as miR221–222, were shown to target
ER 3-UTR and decrease ER protein, but not mRNAs
(165). Amajor advance in the field of synthetic ER ligands
occurred recently with the identification of compounds
that can discriminate the two ER isoforms and selectively
bind to ER (as its agonist PPT (1,3,5-tris (4-hydroxy-
phenyl)-4-propyl-1H-pyrazole) and antagonist side-chain
pyrazoles) (166) or ER, eg, the selective agonist DPN
(2,3-bis (4-hydroxyphenyl) propionitrile). Unfortunately,
the use of SERMs to target neural cells for clinical appli-
cation is quite limited to date, due to still poor knowledge
of the precise molecular targets of these molecules in the
CNS, and the lack of pharmacokinetic data reporting the
levels of permeability across the BBB (167).
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v. Membrane receptors - GPR30
With a structure completely different from the intra-
cellular receptors previously described, another molecule,
an orphan 7-transmembrane receptor, GPR30,was found
to be able to recognize and bind estrogens. GPR30 is a
G-protein-coupled receptor that can bind 17-estradiol in
the nanomolar range, thus with an affinity for the hor-
mone with an approximate ten-fold lower than the intra-
cellular receptors (168). GPR30 is present in the cell mem-
brane and in the endoplasmic reticulum. In different
model systems, the activation of GPR30 is mediated by
17-estradiol and has been associated with several func-
tions, including Ca mobilization (169–171), cAMP
production (168), activation of protein kinases (171,
172), activation of specific ion channels (173) and mod-
ulation of gene expression (174). Yet, themechanisms un-
derlying the intracellular activities of GPR30 are still un-
clear. A recent study showed that upon activation, the
GPR30 formshetero-oligomer complexeswithCa-AT-
Pase and inhibits its activity through tyrosine phosphor-
ylation of the pump (175). It is likely that the receptormay
interact with several intracellular signal transducers
through mechanisms that may change depending on the
cell type. GPR30 is expressed in macrophages and in mi-
croglia (bothprimary cultures fromneonatal rat brain and
BV-2 cells), where it was shown to inhibit the production
of cytokines and oxidative stress-related genes following
stimulation by LPS (176) or hypoxia (177). GPR30 phar-
macology has been the subject of several studies. In breast
cancer cells, GPR30 is activated by the ER antagonist ICI
182 780 (178), Tamoxifen (179), and selective ligands for
GPR30 have been identified and tested in several systems.
The most investigated synthetic ligands for GPR30 are
currently two steroids known as G-1 (agonist) (180) and
G-15 (antagonist) (181, 182); both of these ligands can
readily cross the BBB.
b. Which ERs are expressed in microglia of the adult,
mature brain?
ThepresenceofER inmicrogliawas reportedby several
authors, and a large number of reports highlighted the
anti-inflammatory action of estrogens in microglia cells,
cultures and living animals. However, the abundance and
type of ER expressed in microglia remains an object of
discussion because of the large discrepancies in reports
from different laboratories. Three major elements con-
tribute to the inconsistencies in the literature:
Source of microglia and culture conditions.
Microglia studies are carried out in retroviral immor-
talized cells; primary cell cultures from the neonatal or
adult brain; pluripotent stem cells differentiated in vitro;
and cells directly dissociated from embryonic, neonatal or
mature brainswith a variety ofmethodologies. Functional
(183) as well as more recent genome-wide transcriptomic
studies (184) demonstrated substantial changes in the ac-
tivity and transcriptome of FACS-sorted or cultured mi-
croglia and in microglia in the different stages of activa-
tion. This is not surprising in view of the plasticity of these
cells and suggests that the expression of ERs is likely to
change depending on the model system utilized. Indeed,
studies carried out inmicroglia cell lines showed that ER
and ER mRNA content changes significantly with the
number of passages (185). Considering that the growth
factors present in the serum and the estrogenic activity of
phenol red may activate ERs, it is conceivable that the
culture media may represent a further element affecting
the expression of these receptors.
Microglia sex.
Generally, when primary cultures are established, both
sexes are utilized, and even for the available cell lines, the
sex of origin (N9 and M4T.4 are male and BV-2 and
C8-B4 are female) (185) is not taken into consideration.
Current technology for thequantitativeanalysis of ERgene
expression.
Our ability to verify the expression of ERs by immuno-
histochemical methodologies has been hampered by the
minute dimensions of these cells, the low concentration of
these receptors and the lack of a reliable and constant
source of high-affinity antibodies.
The analysis of the literature on whole genome direct
sequencing of microglia from adult brains clearly shows
the presence of ER, but not ER mRNA (Table 2). The
relative concentration of thismRNA is comparable to that
Table 2. Nuclear Receptor expression in microglia
Source of microglia Method of isolation
ER ER GPR30 AR PR GR MR References
mRNA content (RPKM*)
BV-2 - 0.0 0.0 0.0 0.0 0.0 3.0 0.0 Crotti et al. (193)
Adult mouse whole brain CD11b  magnetic separation 1.5 0.0 1.5 0.1 0.0 42.2 3.5 Maggi et al. Unpublished data
Adult mouse whole brain Percoll/FACS 1.4 0.0 0.3 0.0 0.0 196 0.0 Lavin Y et al. (195)
Mouse brain cortex FACS 3.4 0.0 0.6 0.0 0.1 11.9 1.8 Zhang Ye et al. (194)
Mouse brain cortex Single cell RNAseq 0.02 0.00 0.05 0.00 0.00 1.5 0.05 Zeisel et al. (316)
Spinal cord Percoll/ CD11b- magnetic separation 0.1 0.0 n/a 0.0 0.0 2.9 0.6 Chiu et al. (317)
* Reads Per Kilobase of transcript per Million mapped reads.
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for the mineralocorticoid receptor (MR) and is consider-
ably lower than that for the mRNAs encoding the gluco-
corticoid receptor (GR),while noARwas found (Table 2).
These data appear to be consistent with regard to the rel-
ative abundance of the different receptors possibly be-
cause all studies utilized microglia dissociated from adult
brains. Unfortunately, at present no data are available
from the neonatal brain and primary cultures. In keeping
with these findings are the results of the studies by Sierra,
who first published a systematic analysis on the presence
of selected steroid receptors inmicroglia isolated from the
adult brain by cell sorting. Sierra reported the presence of
ER, GR and MR (27), but no detectable expression of
ER, AR and PR. Staining with ER antibodies revealed
that this receptor is expressedmostly in the cytoplasmnear
the nucleus and in the cell processes (27, 186). Interest-
ingly, not all microglia cells were stained, and the use of
electron microscopy (EM) enabled visualization of label-
ing for ER in microglia processes in close apposition to
neuronal dendritic spines. Immuno-detection of ERs in
neonatal cultures ofmicroglia showed both ER and ER
(138). The finding that ER is low at P3 and increases
rapidly to reach adult levels at day P21 (26) suggested that
the expression of these receptors may change in response
to environmental cues. After treatment with LPS, ER
(together with GR and MR) is downregulated, providing
evidence that the functional status of microglia may in-
fluence the expression of these genes, which in adult an-
imals does not appear to be influenced by the hormonal
status or sex (27, 187). The high reproducibility of these
results in different laboratories sheds light from earlier
reports on the presence of ER or AR expression in mi-
croglia from healthy adult brains (188, 189). Neverthe-
less, ERmay be expressed in microglia isolated from the
spinal cord (190). Transformed cell lines (eg, the murine
BV-2 and N9 cells) express ER, and ER mRNA is not
present (BV-2) (191) or present at low levels (N9) (28,
192). Direct RNA sequencing of BV-2 transcriptome
failed to detect mRNAs for all ERs (193); however, in this
latter report, the low expression of GR suggests that the
sensitivity of the assay used was not optimal when com-
pared to other whole-genome RNA sequences.
With regard to GPR30, the results of several whole-
genome RNA sequencing data (194, 195) point to its ex-
pression in the adult brainmicroglia, and immunostaining
experiments carried out in ratmicroglia from the neonatal
brain showed its presence (176).
c. Estrogen activity in microglia
We are at an early stage in our understanding of estro-
gen influences on microglia activity, and the limited num-
ber of studies available have concentrated on the anti-
inflammatory actions of estrogen. Very little is known
with regard to the role of this hormone in the microglia
functions reported above. For instance, considering the
relevance of estrogens in shaping neuronal circuitries dur-
ing the sexual differentiation of the CNS, it is surprising
that the no investigator addressed the study of the role of
estrogens in microglia-dependent synaptic pruning. Sim-
ilarly, very little attention has been given to the effects of
these hormones on microglia trophic and repair abilities
despite the well-known neuronal protective actions of es-
trogen. The following paragraphs will review the current
literature on the anti-inflammatory effects that estrogen
have in microglia.
i. Estrogen blockade of microglia activation after acute
stimulation with inflammatory stimuli
There is a general consensus on the ability of estrogens
to limit the microglia proinflammatory status after short
exposure to bacterial lysates (196), viruses (197), unmeth-
ylatedCpGoligonucleotides (198), orhypoxia (199, 200).
The hypothesis of the anti-inflammatory potential of es-
trogen was based initially on the in vitro observation that
17-estradiol prevented the morphological changes in-
duced by LPS and the concomitant synthesis of proinflam-
matory molecules (such as MMP9, prostaglandin E2,
iNOS with ROS production) (196). These findings were
subsequently reinforced by investigations on the anti-in-
flammatory potential of the synthetic ligands of ERs, such
as tamoxifen and raloxifene, and natural estrogens, such
as genistein, daidzein, andkaempferol, thatwere shown to
attenuate the-amyloid peptide or LPS-inducedmicroglia
proinflammatory phenotype by inhibiting the synthesis of
TNF, IL-1, MCP-1 or MIP2 in a dose-dependent man-
ner (138) or the production of other inflammatory mole-
cules, such as nitric oxide and ROS. These effects were
blocked by prior treatment with ICI 182 780 (201–203).
Most of these studies were performed in BV-2 cells or
primary cultures of microglia either alone or mixed with
astrocytes. Which of the two intracellular isoforms of ER
is responsible for the anti-inflammatory properties of es-
tradiol remains controversial, andbothERandERmay
trigger anti-inflammatory responses in the presence of
high concentrations of ligand. The use of isoform-specific
modulators, such as PPT or DPN, showed that PPT-acti-
vated ERwasmore effective thanDPN-induced ER for
the inhibition of microglial production of IL-1, IL-1,
TNF-, andCOX-2.This suggested thatERplays amore
significant role than ER in diminishing the inflammatory
response of microglia. However, an increase in ER ex-
pression following treatment with 17-estradiol or DPN
in rat primary microglia provided greater attenuation of
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NO production, thus suggesting ER also plays a role
(204).
ii. Estrogens and neuroinflammation – in vivo
experiments
In vivo studies provided further, strong evidence on the
capacity of estrogens to inhibit the neuroinflammatory
processes. Ovariectomy (ovx) in rodents is clearly associ-
ated with more microglia with a proinflammatory mor-
phology and up-regulation of a large number of markers
of microglia reactivity (including the receptors for the rec-
ognition of inflammatory stimuli and for phagocytosis)
(131, 205). The fact that the administration of estradiol
prior to ovx blocked microglia activation suggested that
the neuroinflammatory reaction ensuing the surgery was
mainly due to the lack of this hormone (131, 205, 206).
Augmented expression of inflammatorymarkers was also
observed in women in postmenopause, particularly in ar-
eas of the brain functionally related to the regions shown
to be most responsive to inflammatory stimuli in rodents.
The extent of microglia activation induced by ovx is
exacerbated by aging. In fact, in ovx old mice, the expres-
sion of inflammatory mediators is much stronger than in
intact mice of the same age. This indicates that low circu-
lating estrogens increase the susceptibility of senescentmi-
croglia to inflammation (207). Most interestingly, studies
with a mouse reporting on the transcriptional activity of
ERs (ERE-Lucmouse (208) showed that the receptor tran-
scriptional activity in the hippocampus diminished signif-
icantly with aging, in spite of the fact that the synthesis of
ERmRNAwas increased and circulating levels of estro-
gens remained quite high (Figure 5). It is therefore plau-
sible thatwith age a formof estrogen resistance is involved
in the impaired ability of microglia to resolve inflamma-
tion, possibly leading to an ever increasing neuroinflam-
matory phenotype. Age is correlated with increased in-
flammation in males as well. Additional studies are
necessary to understand the state of ER activity and local
estrogen production to evaluate the contribution of these
hormones to the activity of senescent microglia in males.
The in vivo local or systemic administration of the endo-
toxin LPS is a commonly usedmodel system for triggering
a robust but transient inflammatory reaction in the rodent
brain and is a valid tool to evaluate the effect of circulating
estrogens in the prevention of acute microglia inflamma-
tory activation. Intra-ventricular or intra-parenchymal in-
jection of LPS demonstrated that the estrogen anti-inflam-
matory actions occurred in all brain areas studied and
required the presence of ER (209). The systemic admin-
istration of LPS enabled the authors to demonstrate that a
peripheral inflammationmay trigger a response also in the
CNS with a rapid activation of microglia and expression
of inflammatory cytokines. The same experimental setting
performed in intact and in ER or ER ko mice indicated
that ERwasmore effective than the
ER isoform in dampening the local
production of inflammatory mole-
cules; ERwas required for the sup-
pression of BBB permeability (210).
The lower number of immunoreac-
tive microglia cells in mice treated
with estrogens and LPS compared
withmice treatedwithLPSalonewas
observed in both males and female
mice (186). Similar to estrogens, the
acute administration of tamoxifen
and raloxifene to ovx, young and
aged mice reduced microglia activa-
tion following LPS stimulation (186,
198) or brain and spinal cord injury
(211–213) pointed to the fact that
these SERMs have an agonist activ-
ity on microglia ER. Long-term
treatment with 17-estradiol or
raloxifene in old ovx females signif-
icantly decreased the number of mi-
croglia cells in the hippocampus
(207) compared to placebo, suggest-
ing that estrogens and SERMs may
Figure 5.
Aging effects on circulating estrogens. The uterus weight as a biomarker of circulating
estrogens shows that, in mice, the activity of the ovaries does not decrease with age: actually at
18 months when mice are not cycling the plasma content of this hormone is higher than in
young, fertile animals. Ovariectomy clearly decreases the circulating levels of the hormone,
showing that organs other than ovaries give a minimal contribution to steroidogenesis.
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be considered as protective treatments against age- and
disease-related pathologies.
iii. Cellular mechanisms of ER-dependent anti-
inflammatory activity
A detailed knowledge of how mammalian innate im-
munity is regulated has developed over the past 15 years.
Membrane and endosomal Toll-like receptors (TLRs) ac-
tivated by a series of small molecules also derived from
parasites, bacteria, fungi, and viruses may dimerize to ini-
tiate a cytoplasmic response leading to theactivationof the
transcription factors responsible for the induction of pro-
inflammatory cytokines, and, in the case of endosomal
TLRs, the induction of type I interferon (IFN). Two im-
portant families of transcription factors activated down-
streamofTLRsignaling are the nuclear factor-B (NF-B)
and interferon-regulatory factors (IRFs). Other transcrip-
tion factors, such as cyclic AMP-responsive element-bind-
ing protein (CREB) and activator protein 1 (AP1), are also
important (214). Currently, the understanding of the mo-
lecularmechanismsof estrogenanti-inflammatory actions
is incomplete because of the multiplicity of responses elic-
itedbyestrogens in theneural, glial and immunecells in the
brain and the variability in the microglial experimental
systems used (as explained above). Nevertheless, several
lines of evidence indicate that estrogens and ERs control
TLR signaling inmyeloid cells (215, 216). EREare present
near genes encoding selected TLR (217), and studies in
microglia and macrophages obtained from wt and genet-
ically modified mice have demonstrated that deletion of
the ER DNA binding site blocks PAMPs/DAMPs-in-
duced upregulation of TLR (218, 219). Aside from this
activity, which suggests that estrogens increase the ability
of microglia to respond to noxious stimuli, we also know
that estrogens inhibit the production of inflammatory cy-
tokines by interfering with TLR signaling through NF-kB
and AP-1. Repeated studies have shown that p65 binding
to its target genes is impaired by estrogens through a non-
genomic pathway involving modulation of the PI3K-de-
pendent pathway (220). The hypothesis that ER inhibits
NF-kB activity by inducing the synthesis of its inhibitory
protein, IkB, remains controversial. Similarly, AP-1may
be involved in the actions of estrogen, as p85 PI3K sig-
naling is involved in the estrogen-dependent blockade of
TLR4 inmacrophages. Estrogens can block the activity of
p38 by interfering with its phosphorylation (221), but
whether this occurs through direct binding to the intra-
cellular ER or through other mechanisms has not been
investigated. These results support the hypothesis that es-
trogens act by reducing the inflammatory response. How-
ever, more recent findings indicate the possibility that es-
trogens exert a more widespread effect on macrophage
activity by controlling their ability to transition among
different activation stages. Using time-lapsed measure-
ments of inflammatory cytokine production, one study
demonstrated that estrogensmay accelerate the resolution
of LPS-induced inflammation by blocking IL-1 synthesis
and increasing production of the anti-inflammatory IL-10
(222). The mechanism involved is of particular interest
because in the absence of lymphoid cells that produce IL-4
to quench the inflammation, ERwould induce synthesis
of SOCS3 through direct regulation of the Socs3 gene pro-
moter in microglia. SOCS3 is a transcription factor that is
instrumental for the synthesis of IL-10, the main cytokine
involved in the onset of the acquired deactivation status
(223). Thus, through this action, estrogenwould augment
the intrinsic ability of macrophages to end the proinflam-
matory phase (Figure 6.). This anti-inflammatory activity
of ER would be even more valuable in the presence of
other inflammatory cells that can terminate macrophage
inflammation by secreting IL-4. In fact, this cytokine con-
siderably increases the number of ERs in macrophages,
therefore enhancing their anti-inflammatory potential.
Thus, these studies indicate that the presence of the hor-
mone estrogen and its ER isoform facilitates both intrin-
sic and extrinsic programs for the resolution of inflam-
mation and the direction of the LPS-stimulated immune
cells toward the IL-10-dependent phenotype (acquired de-
activation) responsible for tissue remodeling and restora-
tion of homeostatic conditions (222).
This estrogen activity is particularly valuable in the case
of chronic inflammation and in aging brains, where the
maintenance of the microglial proinflammatory status
may cause neuronal damage and could thus provide an
explanation for the neuroprotective effects of estrogens
demonstrated in models of neuronal injury and neurode-
generation (224, 225).
Estrogens: protective or risk factors in brain injury and
neurodegeneration?
Numerous studies using animal models in in vitro ex-
plant cultures or in observational studies and clinical trials
involving humans have suggested that ovarian hormones
play an important role providing women protection
against stroke and neurodegenerative diseases (157, 226–
229). However, the mechanisms that enable such effects
have not been fully elucidated. Dissecting the cell types
targeted by estrogen has been slowed by the fact that ERs
are expressed by all neural cells, and the neuroprotective
effects likely result from receptor activation in more than
one cell system. Furthermore, the cells involved may
change depending on the nature of the disorder. This has
broad implications for the selective targeting of ERs in the
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treatment of neurodegenerative conditions due to disease
or injury, particularly in aging and in the postmenopause.
a. Estrogens and stroke or hypoxic neuronal death
In experimental models of stroke (middle cerebral ar-
tery occlusion, MCAO), 17-estradiol attenuated cell
death resulting from ischemic injury and promoted neu-
ronal survival and tissue integrity (157, 226). As stroke
activates a significant microglial reaction, the question
raised by these findings was whether the neuroprotective
effects of estrogens are dependent on their anti-inflamma-
tory activity and their ability to modulate the synthesis of
neuroprotective factors, such as IGF-1, inmicroglia (230).
In this experimental model, the protective effect was ob-
served only when estradiol was administered immediately
rather than weeks after ischemia. This may suggest that
estrogens should be present at high levels when microglia
become activated; therefore, its primary target should be
microglia. However, the role that microglia play in
MCAOwas clearly demonstrated using the Cre-loxP sys-
tem, which selectively deletes ER in cells of myeloid lin-
eage (Cre recombinase under the control of the lysozyme
Mpromoter) or inneurons (Cre recombinaseunderCAM-
KII promoter). The neuroprotective role of 17-estradiol
in MCAO was maintained only in mice that possessed
monocytes without ER, thus leading to the conclusions
that neuronal ER mediates the neuroprotective role of
estrogens and thatmicroglia ER is dispensable, at least in
stroke. The study was performed in male and female mice
showing superimposable outcomes (231). However, it is
worth noting that the results obtained with this model
have been the subject of discussion because the recombi-
nation in microglia does not appear to be very efficient
(232).
b. Demyelinating diseases
Multiple sclerosis (MS) is a demyelinating disease char-
acterized by a strong inflammatory component that is the
main contributor to myelin sheath destruction and an en-
suing progressive paralysis. The fact that MS affects
women twice as often as men and that women may un-
dergo clinical remission in the late stages of pregnancy
suggests that sex hormones play a role in the development
of this disorder (233). Indeed, clinical data and studies in
animal models of MS (eg, experimental autoimmune en-
cephalomyelitis [EAE]) support this hypothesis by dem-
onstrating that estrogens ameliorate EAE severity in both
males and females (234, 235). However, the mechanisms
Figure 6.
Estrogen and microglia functions. Estrogens regulate microglia inflammatory potential by interfering with the process of NFkB activation (a)
and by facilitating the transition to the stages where microglia exert neuroprotective functions (b), possibly including the maintenance and pruning
of dysfunctional synapses (c).
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through which estrogen exerts its beneficial effects in MS
requires further investigation because ERs are present in
all neural cells affected by MS, including neurons, oligo-
dendrocytes, Schwann cells (236), andmicroglia. Consid-
ering the strong neuroinflammatory component of this
disease, estrogen could act in microglia by lessening its
inflammatory reaction or minimizing the infiltration of
circulating lymphocytes andmonocytes. This has been in-
vestigated in the EAE model using genetic and pharma-
cological approaches. Most studies based on the admin-
istration of isoform-specific ligands of ERs (237) and ER
KOmice as myeloid cell donors (238) indicated a key role
for ER in the protective effects of estrogen in EAE.How-
ever, ER also may play a role in demyelinating disorders
(239, 240). The discrepancies in these previous results and
conclusions may be due to differences in the experimental
model used (EAE; or demyelination induced by Theiler’s
virus or cuprizone), the time at which the analysis was
carried out and the fact that the two receptors may have
different functions. As suggested by the work of Brown et
al (210), the major involvement of ER might be relative
to its capacity to control the permeability of peripheral
cells through the BBB. The activated ERmight facilitate
peripheral lymphocyte migration into the CNS by secret-
ing the interleukins that are necessary for dampening neu-
roinflammation. Indeed, studies performed in B cell-defi-
cient mice have shown that IL-10 administration
significantly improves the pathology (241). Finally, it is
important to emphasize that not allMS animalmodels are
applicable for studying the effects of sex hormones. For
instance, cuprizoneadministrationdisrupts the estrous cy-
cle, limiting the ability to establish sex differences (242).
c. Neurodegenerative diseases
Alzheimer’s disease
Dementia is present in 16%ofwomen and 11%ofmen
aged over 71 years. This higher incidence in women was
observed previously in age-matched groups, starting from
60–64 years up to 95 years of age. Therefore, it cannot be
attributed to women having a longer life longevity. In
women, -amyloid accumulation is greater (243, 244)
than inman (245, 246). This appears to be a characteristic
feature of Alzheimer’s Disease (AD) because no evidence
of sex prevalence has been reported for mild cognitive
impairment (MCI) or frontotemporal lobar degeneration
(FTLD). Most animal models of AD (Tg2576, APPswe/
PSEN1E9,APP23,APPswexPS1, and3xTg-AD) reproduce
the same sex specificity of A accumulation and show a
poorer behavioral performance than those reported in hu-
mans (247–251). It remains to be established whether the
lack of ovarian functions plays a role in the sex-related
differences in the incidence of AD. In the sporadic forms
of AD, the association of homozygous single nucleotide
polymorphisms (SNP) of the genes ESR1 (rs9340799,
rs2234693; rs2228480) and ESR2 (rs4986938) with
APOE4 (the best established genetic risk factor for AD)
(112, 252, 253) conferred an increased risk of cognitive
impairment in both sexes, with a higher prevalence in
women. The explanation for the sex dimorphic effect of
this associationmay reside in the fact that estrogen affects
cholesterol and lipid transport, and in the brain, estrogen
regulates the expression of low-density lipoprotein (LDL)
receptor-related protein (LRP),which has been implicated
in A processing. These observations suggest that an im-
paired ER signaling may constitute a predisposing factor
to AD, but by itself, it is not sufficient to increase the risk
of developingAD.Nevertheless, an understanding of how
a lack of estrogens can modify the course of the disease
would be extremely valuable from both therapeutic and
social standpoints.
For many years, ApoE4 has been considered the best
known risk factor forADpathology and accounts for only
10%–20%of the sporadicAD risk.More recently, several
independent genome-wide association studies (GWAS)
have identified newcommonvariants associatedwith spo-
radic AD (253). These findings have contributed to the
diverging focus of the AD pathogenesis from the classical
A-centric view towards neuroinflammation (254–261).
In fact, most of the genes associated with sporadic AD
encode proteins relevant to immune cell functions (eg,
CD33 (257, 258, 262), CLU, BIN1, PICALM, CR1,
CD2AP, EPHA1, ABCA7, MS4A4A/MS4A6E (254–
258), and TREM2 (259, 260)). For instance, the R47H
variant of the TREM2 (Triggering Receptor Expressed on
Myeloid cells 2) gene, was linked to the onset of AD with
a probability comparable to that for ApoE4 (259–261).
Epidemiological studies further argue for a relevant role of
neuroinflammation in AD because pathologies character-
ized by high levels of inflammation, such as vascular dis-
orders and metabolic diseases, increase the risk and prev-
alenceofAD(112, 115, 116). For example, the risk forAD
is augmented by 60% in patients with diabetes mellitus
(DM) (114). Thus, the influence of estrogens onmicroglial
functions may play a role in AD. In animal models of AD,
17-estradiol increased microglia viability in vitro and in
vivo, whereas in humans, 17-estradiol enhanced the up-
take of A in human cortical microglia (263), possibly by
increasing the expression of the complement protein C3
(264), which plays a pivotal role in cytokine-induced ac-
tivation of microglial phagocytosis (265). Finally, estro-
gens were shown to upregulate microglial proteasome ac-
tivity through the p42/44 MAPK pathway, which is
critical for a rapid and efficient turnover of oxidized or
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otherwise damaged proteins and therefore maintains mi-
croglial homeostasis in response to A-induced activation
and metabolic stress (266, 267). In APP23 mice overex-
pressing human amyloid precursor proteinwith the Swed-
ish mutation, ovary ablation increased microglia activa-
tion at A deposits and facilitated the progression of these
cells toward a highly reactive state (206). Long-term ad-
ministration of 17-estradiol blocked this effect and de-
creased microglia reactivity compared to control animals.
In the same study, estrogens were shown to inhibit A-
induced expression of the scavenger receptor in macro-
phage cells. Considering that estrogen facilitates the res-
olutionof the inflammatoryprocess (222), itmayalsoplay
a role in downregulating oxidative stress resulting from
microglia hyperactivity. Despite the many lines of evi-
dence that indicate estrogens have positive effects on the
risk for AD, mixed results have been obtained with HRT
when it was used to counteract the development and pro-
gression of AD. There are reports pointing to a beneficial
role of long-term HRT on the risk of AD and the age at
onset in postmenopausal women (268–270), whereas
other reports question the overall benefits (271–273) of
HRT. These discrepancies may be due to preexisting ge-
netic and hormonal differences, the time at which HRT
was started (274), the timing of the early onset of a neu-
rodegenerative disease, and the type ofHRT (eg, presence/
absence of progesterone). Progesterone treatment inhib-
ited E2-mediated induction of neurotrophin expression
and spatial memory performance (275). Similar effects
were observed on A accumulation after continuous pro-
gesterone treatment in adult female 3xTg-ADmice. How-
ever, the treatment had no effect by itself, but it counter-
acted thebeneficial effect ofE2onAaccumulation (276).
Nevertheless, the observation that cholinergic activity is
decreased by continuous treatments in the hippocampus
of ovx female rats but enhanced by cyclic treatment with
17-estradiol and progesterone (277) suggests that treat-
ments designed to mimic the natural hormonal fluctua-
tions that occur during the ovarian cycle might have ben-
eficial effects on AD-related disorders. Indeed, it has been
described that in female 3Tg-ADmice, cyclic progester-
one delivery counteracted the increase in A resulting
from ovx, and led to an enhancement of the A-lowering
effect of E2, alongwith significant improvements inwork-
ing memory and visual attention (251). Moreover, pro-
gesterone treatment induceda reduction in tauhyperphos-
phorylation, thus suggesting a beneficial effect of cyclic P4
treatment in combination with E2 replacement in lower-
ing the hallmarks of AD.
Parkinson’s disease
Sex is one of the strongest risk factors for Parkinson’s
disease (PD), as men have a 2–fold greater relative risk for
developing PD than women of all ages. Furthermore, the
phenotypic characteristics and symptomatology of the
disease are also sexually dimorphic (278). Sex-specific dif-
ferences have been reported in the gene expression profiles
of neurons obtained from the substantia nigra (SN) of PD
patients, which may indeed underlie the sexual dimor-
phism in the disease etiology, symptoms and responses to
therapy (279). Themale prevalence of PD is also observed
in PD animal models. Injections of neurotoxins (MPTP or
methamphetamine in mice and 6-OHDA in rats) reduced
the number of dopaminergic neurons in the SN and the
dopamine levels in the striatum, with a higher potency
observed inmalesusing lowdosesofneurotoxins, possibly
mimicking the early stages of PD (280, 281) (282). The sex
prevalence in PD may be associated with intrinsic differ-
ences in the brain structures affected by the disease, aswell
as with sex-related environmental factors, as both events
are related to estrogen. In fact, the organization of the
SN-striatal (SNDA) dopaminergic system is sexually di-
morphic, with males presenting a higher number of neu-
ronal cells and regulatory networks, potentiated adaptive
responses to psychomotor stimulants and upregulated ex-
pressionof genes related to familial PD (279).Considering
the role that estrogen plays in brain development, and
particularly its influence on the dopaminergic system, the
sex differences in theNSDA systemmay be determined by
the actions of estrogen on brain cells and somehow favors
PD development in men. On the other hand, strong evi-
dence supports the hypothesis that estrogens contribute to
the sex-related prevalence of PD in adults. This evidence
includes the following: the inverse correlation between
circulating estrogens and the severity of PD symptoms in
women (283), the higher risk of PD in women with early
natural or surgical menopause (284, 285) and the higher
prevalence of PD in climacteric women in comparable age
groups (283, 286). Furthermore, in animal studies of PD,
estrogens were consistently shown to reduce the toxin-
induceddepletionofDA in the female striatum (280, 281).
So far, no firm hypothesis has been put forward to ex-
plain how estrogens affect the manifestation of PD in fe-
males. The current view suggests that accumulation of
misfolded proteins, mitochondrial and endosomal dys-
function and oxidative stress are the major biochemical
mechanisms underlying the pathogenesis PD (287). How-
ever, a genetic association between a neuroinflammatory
deficit and the pathogenesis of PD is still missing. As in the
case ofAD,microglia activation is strongly involved in the
manifestation of PD, as well as a consequence or a cause
of the selective vulnerability of neurons that produce do-
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pamine, a highly reactive chemical that generates oxida-
tive species and adds to themalfunctioningmitochondria,
lysosomal and protein aggregates toxicity. The following
key features link microglia to the pathological hallmarks
of PD: i.) highermicroglial density in themidbrain relative
to other brain areas (32, 288), likely as a result of the local
oxidative environment; ii.) microglia proliferation in-
duced by dopaminergic toxicants specifically in the SN,
which is general sign of brain damage that is also observed
in AD (289); the inflammatory response in the SN is dif-
ferent from other brain regions, such as the striatum or
olfactory bulb, as it occurs independently of IL-1; iii.) the
delivery of LPS in the SN induces microglia activation,
which selectively kills dopaminergic neurons and causes
stable motor deficits (interestingly, serotoninergic neu-
ronsof the SNaswell as neurons in the cortexand striatum
are sparedby this inflammatory insult (290, 291)); and iv.)
damaged dopaminergic neurons specifically release -sy-
nuclein and neuromelanin aggregates that are potent trig-
gers of microglia activation (292). Thus, microglia de-
rangement can be considered as an “environmental”
factor that may participate, either alone or in association
with genetic variants, in the predisposition to PD.
Considering the sexual dimorphism in neuronal struc-
tures and functions affected in PD and the effects of es-
trogens on microglia, the logical question to be asked is
whether estrogen may delay the onset and reduce the
symptomatology of PD in females by targeting microglia.
The fact that ER was not localized to DA neurons of the
striatum, whereas ER, ER and GPR30 were expressed
by microglia and interneurons in this brain region (293,
294) may point to the involvement of cells other than do-
paminergic neurons that mediate hormonal neuroprotec-
tion, and microglia may certainly be taken into consider-
ation. Although still limited, the available literature
provides two main lines of evidence that strongly support
the link between estrogen actions in microglia and neu-
roprotection in PD: the sexual diversity in microglia re-
activity, which triggers neuronal death inmaleswhile pro-
viding neuroprotection in females, and the ruinous effects
of menopause/ovariectomy on neuroinflammation in fe-
males. In fact, a single peritoneal injection of LPS induces
the selective loss of dopaminergic neurons in the SN and
motor behavior deficits in male mice, while repeated in-
jections of the endotoxin are necessary to induce neuro-
toxicity in females (295) (296). In line with this finding,
estrogens reduce microglia activation following LPS ad-
ministration through the inhibition of theMac-1 receptor
and PHOX protein complex, which regulate intracellular
and extracellular ROS production (209, 297) (56). Ac-
cordingly, the genetic ablation of ER in mice increases
Mac-1 expression in microglia (209). Thus, these results
strongly suggest a link between the activity of estrogen in
microglia and the peculiar reactivity of these cells in fe-
males (209). Other approaches that more closely mimic
the pathology of PD showed that the expression of in-
flammatory mediators, such as TNF, IL-1, IFN and
iNOS, are increased in the male NSDA system and it is
associated with an earlier and greater reduction in the
striatal dopamine content in male mice compared to fe-
male mice (298). Accordingly, Morale et al showed that
the toxic potential of activatedmicroglia followingMPTP
injury is inversely proportional to the levels of circulating
estrogens (299). Thus, it appears that the link between
estrogen actions in microglia and female microglia reac-
tivity may prove beneficial for the manifestation of PD.
More recently, it was shown that the expression ofMac-1
and other neuroinflammatory genes is increased by ovx in
the forebrain of middle-aged female rats, and this effect
was reverted by the chronic administration of estrogens
(300). In agreement with these findings, increased expres-
sionof neuroinflammatory geneswasobserved in the fore-
brains of pre- and postmenopausal women (205). Finally,
recent evidence highlighted the role that the renin-angio-
tensin systemplays inmicroglia and showed this system to
bemore potentiated inmales, leading to a higher neuronal
loss in the SN (301),while its downregulationby estrogens
results in reduced oxidative stress, neuroinflammation
and neurodegeneration in females (302, 303).
In summary, the above mentioned studies allow one to
draw a tentative summary of themicroglial pathways that
may play a role in the beneficial effects of estrogens on
neurodegeneration. These effects include the following: i)
the reduction of intra and extramicroglial oxidative stress
through the restoration of mitochondrial functions and
potentiation of reductive enzymatic systems; ii) the mod-
ification of damage-activated intracellular signaling that
provides a faster healing process through the adjustment
of microglia reactivity; and iii) altogether, these observa-
tions support the view that communication between es-
trogen and microglia is one the mechanisms that reduce
the risk of PD in premenopausal women.
Concluding remarks and future directions
Given the involvement of the inflammatory process in
neurodegenerationand theanti-inflammatorypotential, it
seems reasonable to further evaluate how the actions of
estrogen in microglia might influence the onset and pro-
gression of neurodegenerative diseases. However, in un-
dertaking these studies, we should consider the numerous
factors that can constitute a confounding element in the
interpretation of the results. A summary of the mecha-
nisms that aging and the lack of estrogens may perturb in
microglia is shown in Figure 7.
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The main factor to be taken into consideration is the
model system that is used to study the effects of the hor-
mones; the major limitation of primary cultures of neo-
natalmicroglia or transformed cells is represented by their
bias in the ER expression that may not reproduce what is
occurring in microglia of the mature brain. Cultures of
microglia isolated from the adult brain may be a better
model. However, the low recovery of the current isolation
procedure represents a major limitation and in addition
the culture would not provide these cells with the stimuli
necessary for their continuous surveillance and response
to the environment. Perhaps biochemical studies aimed at
studying microglia responsiveness to physio-pathological
or pharmacological stimuli should be assessed in cells
freshly isolated from the brain. The use of Fluorescence
Activated Cell Sorting (FACS) and transgenic mice carry-
ing appropriate reporters for microglia identificationmay
help to overcome the low efficiency of current methodol-
ogies formicroglia isolation. Alternatively, microgliamay
be studied in living organisms. In this case a rigorous char-
acterization of the model used and of the experimental
setting is necessary to obtain reproducible andmeaningful
results because our understanding of estrogen physiology
is still in its infancy. Several authors study estrogen in
intact males to avoid the influence of high levels of this
hormone in the circulation. This, besides limiting the vi-
sion of the research to the sex likely less influenced by
female sex hormones, may give variability in the results
due to the circadian synthesis of testosterone and the pres-
ence/absence of aromatase converting the male sex hor-
Figure 7.
Estrogen-dependent protective effects of microglia.
Several biochemical processes promoted by microglia and regulated by estrogens protect neuronal functions: i.) phagocytosis clears the debris and
dysfunctional proteins (ie, -amyloid) in the parenchyma, ii.) the production of antioxidant systems and enzymes (ie, the renin-angiotensin axis)
limits the oxidative stress; iii.) the healing process is facilitated when damage-activated intracellular signaling pathways are activated, iv.) synaptic
maintenance participates in neuronal signaling. With aging misfolded proteins, cell debris and other inflammatory stimuli accumulate in the brain
parenchyma inducing a continuous stimulation of microglia that with senescence has a decreased phagocitic potential and ability to return to the
surveying state. This initiates a vicious cycle with a progressive increase of the production of inflammatory products detrimental for neuronal
health.
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mone into estrogens. Studies in females rely on the ovx/
hormone replacement paradigm, which limits the
interpretation of the outcome because we know very little
on the endocrine compensatory reactions induced by the
removal of the ovaries. Indeed, we may find totally dif-
ferent effects of pharmacological or hormone replacement
that is dependent on the time of ovx. A better understand-
ing of the physiological functions of estrogens in intact
males at different hours of the day, and in intact females
in the different phases of the cycle, is mandatory to obtain
reproducible and meaningful observations. The selection
of the correct route, dosage and timing of estrogen ad-
ministration is also challenging, as it is in all cells targeted
by estrogen, including microglia, and the response may
dramatically change, leading to conflicting and uninter-
pretable results. To this aim, the use of appropriate re-
porter animals (ie, animals genetically modified to pro-
duce easily measurable proteins in response to a selective
stimulus (304) should be encouraged, as these animals
allow for the spatio-temporal analysis of specific biochem-
ical pathways in single, living animals, thus facilitating the
interpretations of the physiological changes occurring
over time. For example, the available reporter animals
could facilitate the identification of the phase of the cycle
and the cells actively responding to estrogens, whereas
others would facilitate the identification of microglia in
the activated or deactivated status, and these reporter sys-
tems could be bred with each other to obtain the analysis
of multiple end points at the same time.
The other confounding element in the study of the ef-
fects estrogen inmicroglia in vivo is represented by the fact
that all neuronal cells are capable of expressing ERs. For
instance, estrogens target neurons where they may exert a
direct neuroprotective function. This represents a con-
founding element for defining the microglial contribution
to neuronal health. Once more, the use of appropriate
reporter animals would sharpen our vision and facilitate
the study of microglial activity during the development of
the pathology in a specific model of disease. These models
would also be amenable to the study of the effect of age,
nutritional cues and dietary interventions. Indeed, prior
results have shown that age and nutritional status have
major, sex-dependent effects on microglia activity, which
must be taken into consideration in future studies (Sup-
plemental Material - Box 1).
In conclusion, the large body of experimental evidence
provided so far indicates that microglia represent another
target for the neuroprotective actions of estrogen. Indeed,
as a plausible factor driving microglia colonization of the
nervous system, as well as a modulator of microglia reac-
tivity in adult brain, estrogens appear to play a role in the
neurodegenerative process, conditioning the incidence of
these pathologies aswell as the course of their progression.
The lack of a direct, strong linkage between estrogen re-
ceptormutations and neurodegenerative diseases suggests
that these sex hormones do not play a primary role in
promoting the progression of the neurodegenerative pro-
gram, which, in the sporadic forms of these disorders, is
highly multifactorial. However, the impairment of estro-
genic signaling in combination with a lack of other ele-
ments relevant for neuronal health may facilitate the ini-
tiation of the neurodegenerative process as shown by the
studies on the correlation between ER signaling and
ApoE4 (305). The fact that estrogens are not primary con-
tributors, but onlyparticipate in the complex combination
of the events necessary to trigger the neurodegenerative
process, represents the main obstacle for the study of the
effects and the definition of adequate replacement
therapies.
The identification of further correlations between es-
trogen deficiencies and pathologies of the CNS character-
ized by the significant neuroinflammatory component
may provide a means for the study of the efficacy of re-
placement therapies, but time and cost factors may be
unsuitable for what is needed. Such therapies, aimed at
reconstituting the natural defenses of the brain against
neuroinflammation might be less amenable to undesired
collateral effect than exogenousmolecules such as sodium
thiosulfate (306), mito-apocynin (307) or kolaviron (308)
recently proposed for the reduction of neuroinflamma-
tion. In the near future, efforts should be mainly aimed at
a better understanding of the physiology of estrogen ac-
tions in the microglia of males and females. This knowl-
edge is vital for the design of appropriate hormone re-
placement therapies that can overcome the lack of the
natural hormone in targets, sparing their potential nega-
tive effects in reproductive organs.
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